Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptamer Group Regulatory News (APTA)

Share Price Information for Aptamer Group (APTA)

Share Price is delayed by 15 minutes
Get Live Data
0.525    0.00 (0.00%)
Bid:
0.50
Ask:
0.55
Spread: 0.05 (10.00%)
Market Cap: £18.14m
APTA Live PriceLast checked at - London Stock Exchange

Intraday Aptamer Group Share Chart

Form 8.5 (EPT/RI)

31 Jul 2023 09:04

RNS Number : 7196H
Liberum Capital Limited
31 July 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Aptamer Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Aptamer Group Plc

(d) Date dealing undertaken:

28th July 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

ORD 0.1p

 

 

Purchase

 

 

9,779

 

 

 

 

0.042

 

 

0.042

 

 

ORD 0.1p

 

 

 

Sale

 

 

 

 

10,000

 

 

0.04575

 

 

0.04575

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

 31st July 2023

Contact name:

Shivani Ghiraiya

Telephone number:

020 3100 2213

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIGDRXGXDGXB
Date   Source Headline
30th May 20257:00 amRNSUnilever second Optimer development programme
15th May 20257:01 amRNSAptamer Announces New Data at ASGCT
15th May 20257:00 amRNSOptimer licensing agreements and repeat contracts
6th May 20257:00 amRNSAlzheimer’s test advanced and royalty agreement
30th Apr 20257:00 amRNSLicensing agreed for Optimer as vaccine adjuvant
29th Apr 20257:00 amRNS-RAptamer Presenting at ASGCT Annual Meeting
24th Apr 20257:00 amRNS-RNew Corporate Presentation and Investor Factsheet
11th Mar 20257:00 amRNSInterim Results
27th Feb 202512:50 pmRNSTR-1: Standard form notification of major holdings
25th Feb 20257:01 amRNSBlock Listing Interim Review
25th Feb 20257:00 amRNSNotice of Results and Investor Presentation
28th Jan 20252:56 pmRNSIssue of Equity in lieu of Director fees
28th Jan 20257:00 amRNSHalf Year Trading Update
13th Jan 202511:40 amRNSNotification of dealings by a director/PDMR
30th Dec 20247:00 amRNSHolding(s) in Company
19th Dec 20244:44 pmRNSNotification of dealings by a director/PDMR
19th Dec 20247:00 amRNSNew Development Contract
18th Dec 202410:53 amRNSTR-1: Standard form notification of major holdings
16th Dec 202411:28 amRNSNotification of dealings by a director/PDMR
12th Dec 20247:00 amRNSHolding(s) in Company
9th Dec 20243:30 pmRNSNotification of dealings by a director/PDMR
9th Dec 20241:47 pmRNSNotification of dealings by a director/PDMR
9th Dec 20247:00 amRNSGrant of Options and Director Fee Shares
6th Dec 20247:00 amRNSNew Scientific Advisory Board Members
5th Dec 20247:00 amRNSTechnical Update
4th Dec 20247:00 amRNS-RInvestor Webinar
29th Nov 202411:05 amRNSResults of 2024 Annual General Meeting
29th Nov 20247:00 amRNSAGM Statement
7th Nov 20247:00 amRNSAgreement extended with genetic medicines customer
6th Nov 20247:00 amRNSCommercial Trading Update
5th Nov 20247:00 amRNSPosting of Annual Report and Notice of AGM
22nd Oct 20247:00 amRNSFull Year Results for the 12mths to 30 June 2024
17th Oct 20247:00 amRNSNotice of Results and Investor Presentation
16th Sep 20247:00 amRNSDirector Appointment
3rd Sep 20247:00 amRNSAptamer extends contract with Unilever
27th Aug 20247:00 amRNSBlock listing Interim Review
20th Aug 20242:26 pmRNSHolding(s) in Company
16th Aug 20241:04 pmRNSTR-1: Standard form notification of major holdings
14th Aug 202411:34 amRNSTR-1: Standard form notification of major holdings
13th Aug 202412:57 pmRNSResult of General Meeting and Board Changes
1st Aug 20244:33 pmRNSSupplementary Conditional Placing for £60,000
24th Jul 20246:11 pmRNSPosting of Circular and Notice of General Meeting
24th Jul 202412:37 pmRNSFundraise to Raise £2.83 million
8th Jul 20247:05 amRNSUpdate on progress in Unilever partnership
8th Jul 20247:00 amRNSTrading Update
3rd Jul 20247:00 amRNSAgreement to explore Optimer vehicles for siRNA
24th Jun 20247:00 amRNSNew Contracts Announcement for Optimer Development
14th Jun 20247:00 amRNSPartnership with Microsaic Systems
31st May 20244:06 pmRNSHolding(s) in Company
28th May 20249:05 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.